NAOV - NanoVibronix says positive results from UroShield study published in medical journal

NanoVibronix (NAOV) announces that The Journal of Medical & Surgical Urology is publishing an article with positive findings from a study of patients that used its UroShield in real world settings.NAOV shares up 6.3% premarket at $0.85.For the study, 23 patients with reoccurring UTIs were offered to use UroShield for a minimum period of 12 weeks. Objective and subjective measures of improvement were recorded every week.In the findings, patients reported a significant decrease in the number of UTIs and antibiotic treatment, had fewer catheter blockages and catheter changes and pain was reduced significantly by the end of the study.The researchers suggest that the device should be considered as an appropriate treatment in long-term persistent UTIs. "The patient experiences were so profoundly positive that 100% of the study’s participants are continuing to use the device following the conclusion of the study,” stated Brian Murphy, CEO of NanoVibronix.

For further details see:

NanoVibronix says positive results from UroShield study published in medical journal